177 related articles for article (PubMed ID: 30571119)
1. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
4. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of dye-conjugated hepsin inhibitors.
Kim K; Kwon H; Choi D; Lim T; Minn I; Son SH; Byun Y
Bioorg Chem; 2019 Aug; 89():102990. PubMed ID: 31136899
[TBL] [Abstract][Full Text] [Related]
6. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
7. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
8. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Kwon H; Kim Y; Park K; Choi SA; Son SH; Byun Y
Bioorg Med Chem Lett; 2016 Jan; 26(2):310-314. PubMed ID: 26711145
[TBL] [Abstract][Full Text] [Related]
10. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors.
Knaff PM; Müller P; Kersten C; Wettstein L; Münch J; Landfester K; Mailänder V
Biomacromolecules; 2022 Jun; 23(6):2236-2242. PubMed ID: 35593713
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Han Z; Harris PK; Jones DE; Chugani R; Kim T; Agarwal M; Shen W; Wildman SA; Janetka JW
ACS Med Chem Lett; 2014 Nov; 5(11):1219-24. PubMed ID: 25408834
[TBL] [Abstract][Full Text] [Related]
13. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
14. Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Goswami R; Wohlfahrt G; Mukherjee S; Ghadiyaram C; Nagaraj J; Satyam LK; Subbarao K; Gopinath S; Krishnamurthy NR; Subramanya HS; Ramachandra M
Bioorg Med Chem Lett; 2015 Feb; 25(3):616-20. PubMed ID: 25556099
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances of Hepsin-Targeted Inhibitors.
Kwon H; Han J; Lee KY; Son SH; Byun Y
Curr Med Chem; 2017; 24(21):2294-2311. PubMed ID: 28245763
[TBL] [Abstract][Full Text] [Related]
16. Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2.
Duchêne D; Colombo E; Désilets A; Boudreault PL; Leduc R; Marsault E; Najmanovich R
J Med Chem; 2014 Dec; 57(23):10198-204. PubMed ID: 25387268
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Goswami R; Mukherjee S; Ghadiyaram C; Wohlfahrt G; Sistla RK; Nagaraj J; Satyam LK; Subbarao K; Palakurthy RK; Gopinath S; Krishnamurthy NR; Ikonen T; Moilanen A; Subramanya HS; Kallio P; Ramachandra M
Bioorg Med Chem; 2014 Jun; 22(12):3187-203. PubMed ID: 24794746
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract][Full Text] [Related]
20. High-affinity cyclic peptide matriptase inhibitors.
Quimbar P; Malik U; Sommerhoff CP; Kaas Q; Chan LY; Huang YH; Grundhuber M; Dunse K; Craik DJ; Anderson MA; Daly NL
J Biol Chem; 2013 May; 288(19):13885-96. PubMed ID: 23548907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
